Herantis: HERMOD project supporting Phase 2 trial launched
Summary
- Herantis launched the Horizon Europe-funded HERMOD project to support its upcoming Phase II trial of HER-096 in Parkinson’s disease. The launch was expected after the previously announced 8 MEUR grant, and preparations are progressing as planned.
- The company aims to submit the clinical trial application in the final quarter of the current year, with first-patient dosing estimated for the first half of 2027.
- The analyst considers the international consortium’s expertise positive for study execution and patient recruitment, and says the update does not change the analyst’s view of Herantis.
- The trial still requires the remaining funding. The analyst expects Herantis to prioritize non-dilutive financing, such as a licensing agreement, although equity financing remains possible.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 11/12/2026 at 8:50 am EET.
On Wednesday, Herantis Pharma officially announced the launch of the HERMOD research project funded by the Horizon Europe program. The project supports the company's upcoming Phase II clinical trial of the HER-096 drug candidate in Parkinson's disease. The news is an expected step forward, as the company already announced earlier in the year that the project had received an 8 MEUR grant. The press release confirms that the study schedule and preparations are progressing as planned, and the update does not cause any changes to our view of the company. We recently commented on the outlook for Herantis' research program in more detail here.
The HERMOD consortium brings together leading European players, such as Karolinska University Hospital, which is coordinating the project, the Luxembourg Institute of Health, and Skåne University Hospital. We consider the extensive international cooperation with leading academic and clinical experts to be positive, supporting the high-quality execution of the study and patient recruitment. Herantis is the sponsor of the Phase II clinical trial and leads the scientific and technical implementation of the project.
According to the press release, the company aims to submit the clinical trial application (CTA) in the final quarter of the current year, and the dosing of the first patient is estimated to begin in the first half of 2027. The schedule is in line with the company's previously communicated targets. We estimate that the preparations for the trial are on track. Carrying out the trial still requires securing the remaining funding share. We believe that the company will primarily aim for non-dilutive financing solutions, such as a licensing agreement, but equity financing remains a fully possible path forward. We have commented on the financial situation in more detail in connection with the H1 report.